Clinical-stage Swiss biotech targeting CNS disorders.
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Series B Swiss biotech Noema Pharma closed its Series B at 147M USD with EQT Life Sciences joining, to fund four Phase 2 CNS trials. | $147M |
| Mar 2023 | Series B Noema Pharma raised an oversubscribed CHF103M Series B co-led by Forbion and Jeito Capital, with PMC Enterprises, Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus. | $103.5M |